News Home

Intercept Pharmaceuticals Inc (ICPT) is down -4.38% in a Week, Should You Hold?

Thursday, April 14, 2022 12:49 PM | InvestorsObserver Analysts

Mentioned in this article

Intercept Pharmaceuticals Inc (ICPT) is down -4.38% in a Week, Should You Hold?

Intercept Pharmaceuticals Inc (ICPT) is near the top in its industry group according to InvestorsObserver. ICPT gets an overall rating of 60. That means it scores higher than 60 percent of stocks. Intercept Pharmaceuticals Inc gets a 84 rank in the Biotechnology industry. Biotechnology is number 64 out of 148 industries.

Overall Score - 60
ICPT has an Overall Score of 60. Find out what this means to you and get the rest of the rankings on ICPT!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Intercept Pharmaceuticals Inc Stock Today?

Intercept Pharmaceuticals Inc (ICPT) stock is trading at $16.82 as of 12:41 PM on Thursday, Apr 14, a loss of -$0.75, or -4.27% from the previous closing price of $17.57. The stock has traded between $16.72 and $17.48 so far today. Volume today is low. So far 162,039 shares have traded compared to average volume of 838,995 shares. Click Here to get the full Stock Report for Intercept Pharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App